RESUMEN
CONTEXT: Pathogenic germline MAX variants are associated with pheochromocytoma and paraganglioma (PPGL), pituitary neuroendocrine tumors and, possibly, other endocrine and nonendocrine tumors. OBJECTIVE: To report 2 families with germline MAX variants, pheochromocytomas (PCs) and multiple other tumors. METHODS: Clinical, genetic, immunohistochemical, and functional studies at University hospitals in Australia on 2 families with germline MAX variants undergoing usual clinical care. The main outcome measures were phenotyping; germline and tumor sequencing; immunohistochemistry of PC and other tumors; functional studies of MAX variants. RESULTS: Family A has multiple individuals with PC (including bilateral and metastatic disease) and 2 children (to date, without PC) with neuroendocrine tumors (paravertebral ganglioneuroma and abdominal neuroblastoma, respectively). One individual has acromegaly; immunohistochemistry of PC tissue showed positive growth hormone-releasing hormone staining. Another individual with previously resected PCs has pituitary enlargement and elevated insulin-like growth factor (IGF-1). A germline MAX variant (c.200C>A, p.Ala67Asp) was identified in all individuals with PC and both children, with loss of heterozygosity in PC tissue. Immunohistochemistry showed loss of MAX staining in PCs and other neural crest tumors. In vitro studies confirmed the variant as loss of function. In Family B, the proband has bilateral and metastatic PC, prolactin-producing pituitary tumor, multigland parathyroid adenomas, chondrosarcoma, and multifocal pulmonary adenocarcinomas. A truncating germline MAX variant (c.22G>T, p.Glu8*) was identified. CONCLUSION: Germline MAX mutations are associated with PCs, ganglioneuromas, neuroblastomas, pituitary neuroendocrine tumors, and, possibly, parathyroid adenomas, as well as nonendocrine tumors of chondrosarcoma and lung adenocarcinoma, suggesting MAX is a novel multiple endocrine neoplasia gene.
Asunto(s)
Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice/genética , Mutación de Línea Germinal , Neoplasia Endocrina Múltiple/genética , Adolescente , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/genética , Adulto , Anciano , Australia , Preescolar , Familia , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/diagnóstico , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/genética , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/genética , Linaje , Feocromocitoma/diagnóstico , Feocromocitoma/genética , Adulto JovenRESUMEN
The multiple endocrine neoplasia (MEN) syndromes include MEN1, MEN2 (formerly MEN2A), MEN3 (formerly MEN2B) and the recently identified MEN4. Clinical presentations are varied and often relate to the overproduction of specific hormones. Understanding the genetics of each syndrome assists in determining screening timelines. Treatments for each manifestation are dependent on location, risk of recurrence or malignancy, hormone excess and surgical morbidity. Multidisciplinary management should include geneticists, genetic counsellors, endocrinologists and endocrine surgeons.
Asunto(s)
Neoplasia Endocrina Múltiple/diagnóstico , Neoplasia Endocrina Múltiple/genética , Neoplasia Endocrina Múltiple/terapia , Terapia Combinada , Procedimientos Quirúrgicos Endocrinos , Marcadores Genéticos , Pruebas Genéticas , Humanos , Neoplasia Endocrina Múltiple/clasificación , RecurrenciaRESUMEN
Multiple endocrine neoplasia (MEN) has not been reported in baboons, but this condition is well described in humans. An internal database was searched for all cases of concurrent endocrine hyperplasia and neoplasia in baboons. Twenty-four baboons (Papio spp.) with concurrent endocrine hyperplasia and neoplasia were identified. Twenty-one baboons had lesions in two endocrine organs, two baboons had lesions in three organs, and one baboon had lesions in four organs. Ten baboons aligned with the MEN1 classification; 14 baboons did not match any current human MEN classification. We report 24 cases of MEN-like syndrome in baboons. MEN1-like lesions accounted for nearly half (41%) of the affected animals. Genetic analysis of baboons with MEN-like syndrome could further elucidate the mechanisms of MEN and support the use of baboons as animal models for human MEN.
Asunto(s)
Enfermedades de los Monos/patología , Neoplasia Endocrina Múltiple/patología , Papio , Animales , Animales de Laboratorio , Femenino , Masculino , Enfermedades de los Monos/clasificación , Neoplasia Endocrina Múltiple/clasificación , Estudios Retrospectivos , Síndrome , TexasAsunto(s)
Adenoma/genética , Neoplasias de las Glándulas Suprarrenales/genética , Neoplasia Endocrina Múltiple/genética , Paraganglioma/genética , Feocromocitoma/genética , Neoplasias Hipofisarias/genética , Succinato Deshidrogenasa/genética , Adulto , Exones/genética , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple/clasificación , Eliminación de SecuenciaRESUMEN
Multiple endocrine neoplasias are autosomal dominant disorders characterized by the occurrence of tumors in at least two endocrine glands. Two MEN syndromes have long been known and are well characterized: the MEN type 1 (MEN1) and type 2 (MEN2). These syndromes are caused by germline mutations in the MEN1 and RET genes, respectively, and have a different tumor spectrum. Recently, a variant of the MEN syndromes arose spontaneously in a rat colony and was named MENX. Affected animals consistently develop multiple endocrine tumors, with a spectrum that shares features with both MEN1 and MEN2 human syndromes. Genetic studies identified a germline mutation in the Cdkn1b gene, encoding the p27 cell cycle inhibitor, as the causative mutation for MENX. Capitalizing on these findings, heterozygous germline mutations in the human homologue, CDKN1B, were searched for and identified in patients with multiple endocrine tumors. As a consequence of this discovery, a novel human MEN syndrome, named MEN4, was recognized, which is caused by mutations in p27. Altogether, these studies identified Cdkn1b/CDKN1B as a novel tumor susceptibility gene for multiple endocrine tumors in both rats and humans. Here we review the characteristics of the MENX and MEN4 syndromes and we briefly address the main function of p27 and how they are affected by MENX/4-associated mutations.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/genética , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Mutación de Línea Germinal/genética , Neoplasia Endocrina Múltiple/genética , Mutación , Neoplasias de las Glándulas Suprarrenales/patología , Glándulas Suprarrenales/patología , Animales , Humanos , Hiperplasia , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/patología , RatasRESUMEN
Pheochromocytomas and paragangliomas (PCC/PGL) are tumors derived from the adrenal medulla or extra-adrenal ganglia, respectively. They are rare and often benign tumors that are associated with high morbidity and mortality due to mass effect and high circulating catecholamines. Although most PCCs and PGLs are thought to be sporadic, over one third are associated with 10 known susceptibility genes. Mutations in three genes causing well characterized tumor syndromes are associated with an increased risk of developing PCCs and PGLs, including VHL (von Hippel-Lindau disease), NF1 (Neurofibromatosis Type 1), and RET (Multiple Endocrine Neoplasia Type 2). Mutations in any of the succinate dehydrogenase (SDH) complex subunit genes (SDHA, SDHB, SDHC, SDHD) can lead to PCCs and PGLs with variable penetrance, as can mutations in the subunit cofactor, SDHAF2. Recently, two additional genes have been identified, TMEM127 and MAX. Although these tumors are rare in the general population, occurring in two to eight per million people, they are more commonly associated with an inherited mutation than any other cancer type. This review summarizes the known germline and somatic mutations leading to the development of PCC and PGL, as well as biochemical profiling for PCCs/PGLs and screening of mutation carriers.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/genética , Heterogeneidad Genética , Predisposición Genética a la Enfermedad , Paraganglioma/genética , Feocromocitoma/genética , Neoplasias de las Glándulas Suprarrenales/clasificación , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Animales , Comprensión , Humanos , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/genética , Paraganglioma/clasificación , Paraganglioma/diagnóstico , Feocromocitoma/clasificación , Feocromocitoma/diagnóstico , Síndrome , Enfermedad de von Hippel-Lindau/genéticaRESUMEN
Multiple endocrine neoplasias are autosomal dominant disorders characterized by the occurrence of tumors in at least two endocrine glands. Two MEN syndromes have long been known and are well characterized: the MEN type 1 (MEN1) and type 2 (MEN2). These syndromes are caused by germline mutations in the MEN1 and RET genes, respectively, and have a different tumor spectrum. Recently, a variant of the MEN syndromes arose spontaneously in a rat colony and was named MENX. Affected animals consistently develop multiple endocrine tumors, with a spectrum that shares features with both MEN1 and MEN2 human syndromes. Genetic studies identified a germline mutation in the Cdkn1b gene, encoding the p27 cell cycle inhibitor, as the causative mutation for MENX. Capitalizing on these findings, heterozygous germline mutations in the human homologue, CDKN1B, were searched for and identified in patients with multiple endocrine tumors. As a consequence of this discovery, a novel human MEN syndrome, named MEN4, was recognized, which is caused by mutations in p27. Altogether, these studies identified Cdkn1b/CDKN1B as a novel tumor susceptibility gene for multiple endocrine tumors in both rats and humans. Here we review the characteristics of the MENX and MEN4 syndromes and we briefly address the main function of p27 and how they are affected by MENX/4-associated mutations.
Asunto(s)
Animales , Humanos , Ratas , Neoplasias de las Glándulas Suprarrenales/genética , /genética , Mutación de Línea Germinal/genética , Mutación , Neoplasia Endocrina Múltiple/genética , Neoplasias de las Glándulas Suprarrenales/patología , Glándulas Suprarrenales/patología , Hiperplasia , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/patologíaAsunto(s)
Neoplasias de la Tiroides/tratamiento farmacológico , Carcinoma Neuroendocrino , Contraindicaciones , Humanos , Neoplasia Endocrina Múltiple/clasificación , Mutación/genética , Piperidinas/efectos adversos , Piperidinas/uso terapéutico , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas c-ret/genética , Quinazolinas/efectos adversos , Quinazolinas/uso terapéutico , Investigación/tendencias , Síndrome , Neoplasias de la Tiroides/genéticaRESUMEN
Multiple endocrine neoplasia (MEN) syndromes are characterized by tumors involving two or more endocrine glands. Two MEN syndromes have long been known: MEN1 and MEN2,caused by germline mutations in MEN1 or RET, respectively. Recently, mutations in CDKN1B,encoding the cyclin-dependent kinase (Cdk) inhibitor p27, were identified in patients having a MEN1-like phenotype but no MEN1 gene mutations. Currently, the molecular mechanisms mediating the role of p27 in tumor predisposition are ill defined. We here report a novel germline missense variant in CDKN1B (c.678C>T, p.P69L) found in a patient with multiple endocrine tumors. We previously reported a nonsense p27 mutation (c.692G>A, p.W76X) in two patients with MEN1-like phenotype. Functional assays were used to characterize p27P69L and p27W76X in vitro. We show that p27P69L is expressed at reduced level and is impaired in both binding toCdk2 and inhibiting cell growth. p27W76X, which is mislocalized to the cytoplasm, can no longer efficiently bind Cyclins-Cdks, nor inhibit cell growth or induce apoptosis. In the patient's tumor tissues, p27P69L associates with reduced/absent p27 expression and in one tumor with loss-of heterozygosity.Our results extend previous findings of CDKN1B mutations in patients with MEN1-related states and support the hypothesis of a tumor suppressor role for p27 in neuroendocrine cells.
Asunto(s)
Mutación de Línea Germinal , Péptidos y Proteínas de Señalización Intracelular/genética , Neoplasia Endocrina Múltiple/genética , Anciano , Línea Celular , Inhibidor p27 de las Quinasas Dependientes de la Ciclina , Análisis Mutacional de ADN , ADN de Neoplasias/genética , Femenino , Técnicas de Silenciamiento del Gen , Células HeLa , Humanos , Técnicas In Vitro , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Masculino , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple Tipo 1/genética , Mutagénesis Sitio-Dirigida , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Fenotipo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismoRESUMEN
In the past 3 years new insight into the etiopathogenesis of hereditary endocrine tumors has emerged from studies conducted on MENX, a rat multiple endocrine neoplasia (MEN) syndrome. MENX spontaneously developed in a rat colony and was discovered by serendipity when these animals underwent complete necropsy, as they were found to consistently develop multiple endocrine tumors with a spectrum similar to both MEN type 1 (MEN1) and MEN2 human syndromes. Genetic studies identified a germline mutation in the Cdkn1b gene, encoding the p27 cell cycle inhibitor, as the causative mutation for the MENX syndrome. Capitalizing on these findings, we and others identified heterozygous germline mutations in the human homologue, CDKN1B, in patients with multiple endocrine tumors. As a consequence of these observations a novel human MEN syndrome, named MEN4, was recognized which is caused by mutations in p27. Altogether these studies identified Cdkn1b/CDKN1B as a novel tumor susceptibility gene for multiple endocrine tumors in both rats and humans. In this chapter we present the MENX syndrome and its phenotype, and we compare it to the human MEN syndromes; we discuss the current state of knowledge regarding the genes associated to inherited MEN, with a particular focus on CDKN1B; we present recent clinical and basic findings about the MEN4 syndrome and the functional characterization of the CDKN1B mutations identified. These findings are placed in the broader context of how p27 dysregulation might affect neuroendocrine cell function and trigger tumorigenesis.
Asunto(s)
Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Predisposición Genética a la Enfermedad , Neoplasia Endocrina Múltiple/genética , Neoplasia Endocrina Múltiple/metabolismo , Neoplasias Hipofisarias/genética , Animales , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/metabolismo , Femenino , Humanos , Masculino , Neoplasia Endocrina Múltiple/clasificación , Mutación/genética , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas/metabolismo , RatasRESUMEN
BACKGROUND: The rearranged during transfection (RET) V804M proto-oncogene mutation is rare and associated with medullary thyroid carcinoma (MTC). We present 40 members from a total cohort of 107 family members with this mutation. METHODS: Family members were tested for RET mutations, calcitonin levels, and screened for pheochromocytoma and primary hyperparathyroidism (PHPT). Thyroidectomies were performed on 15 members. Surgery and pathology reports were obtained and reviewed. A pedigree was constructed. RESULTS: A high penetrance was found for MTC and simultaneous papillary thyroid carcinoma (PTC; 40%). The incidence of PHPT was low (13%). There were no findings of pheochromocytoma. The course in the first family generation was indolent, with late onset of MTC. The second generation experienced earlier disease development; onset occurred earliest in the third generation. The second generation experienced a higher incidence of PTC than the first. CONCLUSION: This is the largest family with this mutation reported to date. However, it does not fit the classic familial MTC or MEN 2A cancer syndrome. Considering that PTC is not an incidental finding, but the result of an inherited RET V804 M mutation, we propose to identify this phenotypic expression as a unique syndrome consistent with manifestations of MTC, PHPT, and PTC.
Asunto(s)
Carcinoma Medular/genética , Carcinoma Papilar/genética , Hiperparatiroidismo Primario/genética , Neoplasia Endocrina Múltiple/genética , Mutación Puntual , Proteínas Proto-Oncogénicas c-ret/genética , Neoplasias de la Tiroides/genética , Neoplasias de las Glándulas Suprarrenales/genética , Adulto , Anciano , Anciano de 80 o más Años , Sustitución de Aminoácidos , Anticipación Genética , Femenino , Humanos , Italia , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple/clasificación , Linaje , Penetrancia , Feocromocitoma/genética , Proto-Oncogenes Mas , Proto-Oncogenes , Estudios Retrospectivos , SíndromeRESUMEN
INTRODUCTION: The assessment of frequency and type of mutation and differences in prognosis between sporadic and hereditary type of medullary thyroid carcinoma (MTC), based on own DNA analysis, was performed. MATERIAL AND METHODS: The group of 190 persons with hereditary MTC or asymptomatic mutation carriers was analyzed. Patients with sporadic MTC without RET gene mutation were included into control group (708 persons). The recognition of MTC type was based on assessment of family history, physical examination and genetic analysis. The family history consisted of information about MTC, pheochromocytoma and other neoplasms and hyperparathyroidism in relatives. RESULTS: The mutations located in codon 634 of exon 11 were the most often (43% of all mutations and 49% of mutations in syndrome MEN 2A/FMTC). The age of diagnosis was ranged between 7 and 71 years (mean age: 39 +/- 15.2 years, median age: 41 years). In hereditary MTC the mean age of diagnosis was 27 +/- 13.9 years and was significantly lower than in sporadic one, where it was 45.7 +/- 14.3 years. The relationship between diagnosis, age and subtypes of hereditary MTC was assessed--no significant differences in examined subgroups were observed. The mean age of diagnosis in MEN 2A/FMTC and MEN 2A syndrome was 28-29 years, in MEN 2B - 21 years. The overall survival in sporadic MTC after 5 years was 97%, in hereditary MTC - 79%. Analysis performed after excluding suprarenal causes of death revealed no statistically significant differences in overall survival between both subtypes of MTC. CONCLUSIONS: 1. Hereditary MTC is still diagnosed too late, besides of DNA analysis. 2. In hereditary and sporadic MTC the prognosis is comparable.
Asunto(s)
Carcinoma Medular/clasificación , Carcinoma Medular/genética , Proteínas Proto-Oncogénicas/genética , Neoplasias de la Tiroides/clasificación , Neoplasias de la Tiroides/genética , Adolescente , Adulto , Anciano , Carcinoma Medular/diagnóstico , Niño , Análisis Mutacional de ADN/métodos , ADN de Neoplasias , Femenino , Predisposición Genética a la Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/genética , Mutación Puntual/genética , Proteínas Proto-Oncogénicas c-ret , Factores de Riesgo , Neoplasias de la Tiroides/diagnósticoRESUMEN
Dermatologic manifestations of parathyroid-related disorders, although rare in sporadic cases, are not uncommon in familial syndromes. Patients with familial hyperparathyroidism have several types of skin lesions. In multiple endocrine neoplasia 1, patients commonly have angiofibromas (85%) and collagenomas (70%), lesions that show loss of one 11q13 allele, the molecular abnormality in multiple endocrine neoplasia 1. They can also present with lipomas or café-au-lait spots. Cutaneous amyloidosis, an entity that can occur sporadically, has been described in multiple endocrine neoplasia 2a and is usually localized to the interscapular area. Metastatic calcification is an entity commonly encountered in patients with hyperparathyroidism and renal failure. It can be complicated by infections and necrosis. It is best treated by controlling hypercalcemia, hyperphosphatemia, hyperparathyroidism, antibiotics, and analgesia. Parathyroidectomy is reserved for refractory cases. Hypoparathyroidism presenting in the context of polyglandular failure type 1 is characterized by mucocutaneous candidiasis. Pseudohypoparathyroidism, an inherited disorder with end-organ unresponsiveness to parathyroid hormone, is characterized by Albright hereditary osteodystrophy. Patients present with short stature, round facies, brachydactyly, and short fourth or fifth metacarpals.
Asunto(s)
Neoplasia Endocrina Múltiple , Enfermedades de las Paratiroides , Neoplasias Cutáneas , Humanos , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/genética , Neoplasia Endocrina Múltiple/patología , Neoplasia Endocrina Múltiple/fisiopatología , Enfermedades de las Paratiroides/etiología , Enfermedades de las Paratiroides/genética , Enfermedades de las Paratiroides/patología , Enfermedades de las Paratiroides/fisiopatología , Enfermedades de las Paratiroides/terapia , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patologíaRESUMEN
Dermatologists may also encounter patients presenting with skin lesions that reflect an underlying endocrine disorder not commonly seen in daily practice. Some of these endocrine disorders include glucagonoma, neurofibromatosis type 1, McCune-Albright syndrome, multiple endocrine neoplasia, the Carney complex, carcinoid tumors, and mastocytosis. The clinical syndrome classically associated with glucagonoma includes necrolytic migratory erythema, weight loss, diabetes mellitus, anemia, cheilitis, venous thrombosis, and neuropsychiatric symptoms. The hallmarks of neurofibromatosis type 1 are the multiple café-au-lait spots and associated cutaneous neurofibromas. Other presenting features include freckling, peripheral neurofibromas, Lisch nodules, bone abnormalities, tumors, neurologic abnormalities and hypertension. McCune-Albright syndrome is characterized by café-au-lait spots, polyostotic fibrous dysplasia, sexual precocity, and hyperfunction of multiple endocrine glands. Multiple endocrine neoplasia type 2A is characterized by medullary thyroid cancer, pheochromocytoma, and primary parathyroid hyperplasia. In some patients with multiple endocrine neoplasia type 2A, cutaneous lichen amyloidosis may also be present. Multiple endocrine neoplasia type 2B is characterized by medullary thyroid cancer and pheochromocytoma but not hyperparathyroidism. The syndrome also includes mucosal neuromas, typically involving the lips and tongue, intestinal ganglioneuromas and a marfanoid habitus. Multiple endocrine neoplasia type 1 is an autosomal dominant predisposition to tumors of the parathyroid glands (four-gland hyperplasia), anterior pituitary, and pancreatic islet cells; hence, the mnemonic device of the "3 Ps"; multiple cutaneous lesions (angiofibromas and collagenomas) are frequent in patients with multiple endocrine neoplasia type 1. Carney complex may be viewed as a form of multiple endocrine neoplasia because affected patients often have tumors of two or more endocrine glands, including primary pigmented nodular adrenocortical disease (some with Cushing's syndrome), pituitary adenoma, testicular neoplasms, thyroid adenoma or carcinoma, and ovarian cysts. Additional unusual manifestations include psammomatous melanotic schwannoma, breast ductal adenoma, and a rare bone tumor, osteochondromyxoma. Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various humoral factors elaborated by some carcinoid tumors; the major manifestations are diarrhea, flushing, bronchospasm, and cardiac valvular lesions. Mast cell diseases include all disorders of mast cell proliferation. These diseases can be limited to the skin, referred to as "cutaneous mastocytosis," or involve extracutaneous tissues, called "systemic mastocytosis." Patients present with urticaria pigmentosa, mastocytoma, or diffuse cutaneous mastocytosis. Systemic involvement may be gastronintestinal, hematologic, neurologic, and skeletal.
Asunto(s)
Enfermedades del Sistema Endocrino/genética , Enfermedades del Sistema Endocrino/patología , Mastocitosis Cutánea/patología , Neoplasia Endocrina Múltiple/genética , Neoplasia Endocrina Múltiple/patología , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/fisiopatología , Femenino , Humanos , Masculino , Mastocitosis Cutánea/diagnóstico , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/fisiopatología , SíndromeRESUMEN
Multiple endocrine neoplasia (MEN) is characterized by the occurrence of two or more tumors that may be associated with hyperfunction and malignancy. MEN is caused by genetic defects, and two major types, MEN 1 and MEN 2, are recognized. Each type is characterized by the development of tumors within specific endocrine organs. A multidisciplinary approach involving cooperation between endocrinologists, surgeons, oncologists, and radiologists is pivotal for optimizing patient treatment. Imaging plays a vital role in the diagnosis and management of the disease. To contribute effectively, however, the radiologist must understand the range of anatomic and functional imaging modalities used in the assessment of endocrine disorders. In addition, knowledge of the optimal techniques for evaluating the pituitary, thyroid, parathyroid, pancreatic, adrenal, and foregut carcinoid tumors that occur in these MEN syndromes is essential. Finally, an understanding of the spectrum of disease and of the manifestations of each component is crucial for accurate detection, staging, and surveillance in this diverse patient group.
Asunto(s)
Diagnóstico por Imagen/métodos , Aumento de la Imagen/métodos , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/diagnóstico , Técnica de Sustracción , Diagnóstico por Imagen/tendencias , Humanos , Guías de Práctica Clínica como AsuntoRESUMEN
Duodenopancreatic endocrine tumors are the most frequently lethal part of MEN-1. The management of these patients is complicated by the variable hormonal function of the tumors, and the often indolent but occasionally lethal nature of the tumors. This article reviews our current approach to the diagnosis, surveillance and management of these patients.
Asunto(s)
Neoplasias Duodenales/diagnóstico , Neoplasias Duodenales/cirugía , Neoplasia Endocrina Múltiple/diagnóstico , Neoplasia Endocrina Múltiple/cirugía , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/cirugía , Endoscopía , Humanos , Insulinoma/diagnóstico , Insulinoma/cirugía , Neoplasia Endocrina Múltiple/clasificación , Estadificación de Neoplasias , Cuidados PreoperatoriosRESUMEN
Multiple endocrine neoplasias (MEN) are syndromes inherited as autosomal dominant. The application of the techniques of molecular biology has made possible the identification of the genes causing MEN 1 and 2. The gene responsible for MEN 1 belongs to the family of tumor suppressor genes and encodes for a protein named MENIN whose function remains to be elucidated. The identification of mutant MEN 1 gene carriers who are at risk of developing this syndrome requires frequent biochemical screening for the development of endocrine tumors. MEN 2 is a consequence of mutations in the Ret proto-oncogene (c-Ret). This gene encodes for a tyrosine kinase receptor thought to play a role in the development of neural crest-derived tissue. Members of kindred with either MEN 2A or MEN 2B should be screened by direct DNA testing early in life for mutations in c-Ret. Those with the mutation should be advised to have thyroidectomy at five years of age in children with MEN 2A and earlier in children with MEN 2B. Some cases of sporadic MTC are actually MEN 2A or Familial MTC after c-Ret testing is done, therefore routine application of this test is recommended in all cases of apparent sporadic MTC.
Asunto(s)
Proteínas de Drosophila , Marcadores Genéticos , Neoplasia Endocrina Múltiple/genética , Adulto , Niño , Preescolar , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Humanos , Biología Molecular , Neoplasia Endocrina Múltiple/clasificación , Neoplasia Endocrina Múltiple/diagnóstico , Neoplasia Endocrina Múltiple Tipo 1/diagnóstico , Neoplasia Endocrina Múltiple Tipo 1/genética , Neoplasia Endocrina Múltiple Tipo 2a/diagnóstico , Neoplasia Endocrina Múltiple Tipo 2a/genética , Neoplasia Endocrina Múltiple Tipo 2b/diagnóstico , Neoplasia Endocrina Múltiple Tipo 2b/genética , Mutación/genética , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas/análisis , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-ret , Proteínas Tirosina Quinasas Receptoras/análisis , Proteínas Tirosina Quinasas Receptoras/genética , Factores de RiesgoRESUMEN
En este trabajo se presenta el caso de un recién nacido con neoplasia endocrina múltiple, poniéndose énfasis en las diferencias entre los síndromes clásicos y el que ahora se describe. También se comenta la naturaleza de las lesiones proliferativas.
Asunto(s)
Humanos , Masculino , Sistema Urogenital/patología , Neoplasias/congénito , Neoplasia Endocrina Múltiple Tipo 1 , Neoplasia Endocrina Múltiple/clasificación , Recién NacidoRESUMEN
There are three generally accepted multiple endocrine neoplasia (MEN) syndromes: MEN-1, MEN-2A, and MEN-2B. On the basis of their major features, new familial MEN syndromes should manifest (i) a new endocrine tumour combination, (ii) autosomal dominant inheritance, and, possibly, (iii) a nonendocrine component. Acceptance of the last feature as a criterion has conferred candidate MEN status on a number of disorders, including von Hippel-Lindau disease and neurofibromatosis. To regard these conditions as MEN syndromes would require an inappropriate demotion of their predominant nonendocrine manifestations. The role of nonendocrine disorders in MEN syndromes needs reappraisal.